share_log

Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6

Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6

Ascendiant Capital以買入評級啓動對Cyclo Therapeutics的報道，宣佈目標股價爲2.6美元
Benzinga ·  04/22 17:40

Ascendiant Capital analyst Lucas Ward initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces Price Target of $2.6.

Ascendiant Capital分析師盧卡斯·沃德開始對Cyclo Therapeutics（納斯達克股票代碼：CYTH）進行報道，評級爲買入，並宣佈目標股價爲2.6美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論